1-methyl-1,5,6,7-tetrahydro-4H-indazol-4-one oxime

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-methyl-1,5,6,7-tetrahydro-4H-indazol-4-one oxime
• 英文别名: (NE)-N-(1-methyl-6,7-dihydro-5H-indazol-4-ylidene)hydroxylamine
• 化学式: C₈H₁₁N₃O
• 分子量: 165.19
• InChiKey: IBBXMUQUVIMWQT-JXMROGBWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• CONDENSED LACTAM DERIVATIVE
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US20200172543A1

  公开（公告）日：2020-06-04

  The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.

  本发明涉及一种用于治疗神经精神疾病的药物，包括以下化合物（1）的药物学上可接受的盐，作为活性成分。
• Fused pyramidine derivative and use thereof
  申请人：Hamamura Kazumasa

  公开号：US20070010537A1

  公开（公告）日：2007-01-11

  There are provided a fused pyrimidine compound having antagonistic activity against luteinizing hormone releasing hormone, and a medicine containing the compound. A luteinizing hormone releasing hormone antagonist containing a compound represented by the formula: wherein R 1a is a hydrocarbon group which may be substituted or a hydrogen atom, ring A a is a 6-membered aromatic ring which may be further substituted, ring B a is a homocyclic or heterocyclic ring which may be further substituted, W a is an oxygen atom or a sulfur atom, X a1 and X a2 , which may be identical or different, are each a hydrogen atom, a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted, or X a1 and X a2 together may form an oxygen atom, a sulfur atom or NR 3a (wherein R 3a is a hydrocarbon group which may be substituted or a hydrogen atom), and Y a is C 1-6 alkylene which may be substituted or a bond, or a salt or prodrug thereof.

  提供了一种融合嘧啶化合物，具有抗促黄体激素释放激素的拮抗活性，以及含有该化合物的药物。一种促黄体激素释放激素拮抗剂，包含以下式子所代表的化合物：其中，R1a是一个可以被取代的碳氢基团或氢原子，环A是一个可以进一步取代的6元芳香环，环B是一个可以进一步取代的同环或异环，Wa是一个氧原子或硫原子，Xa1和Xa2，可能相同或不同，是每个可以被取代的碳氢基团或杂环基团，或Xa1和Xa2在一起可以形成氧原子、硫原子或NR3a（其中R3a是一个可以被取代的碳氢基团或氢原子），而Y是C1-6烷基，可以被取代或成为键，或其盐或前药。
• FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1657238A1

  公开（公告）日：2006-05-17

  There are provided a fused pyrimidine compound having antagonistic activity against luteinizing hormone releasing hormone, and a medicine containing the compound. A luteinizing hormone releasing hormone antagonist containing a compound represented by the formula: wherein R1a is a hydrocarbon group which may be substituted or a hydrogen atom, ring Aa is a 6-membered aromatic ring which may be further substituted, ring Ba is a homocyclic or heterocyclic ring which may be further substituted, Wa is an oxygen atom or a sulfur atom, Xa1 and Xa2, which may be identical or different, are each a hydrogen atom, a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted, or Xa1 and Xa2 together may form an oxygen atom, a sulfur atom or NR3a (wherein R3a is a hydrocarbon group which may be substituted or a hydrogen atom), and Ya is C1-6 alkylene which may be substituted or a bond, or a salt or prodrug thereof.

  提供了一种对黄体生成素释放激素具有拮抗活性的融合嘧啶化合物，以及一种含有该化合物的药物。一种黄体生成素释放激素拮抗剂含有由式表示的化合物： 其中 R1a 是可被取代的烃基或氢原子、 环 Aa 是可被进一步取代的 6 元芳香环、 环 Ba 是可被进一步取代的同环或杂环、 Wa 是氧原子或硫原子、 Xa1 和 Xa2（可以相同或不同）各自是氢原子、可被取代的烃基或可被取代的杂环基，或 Xa1 和 Xa2 可共同形成氧原子、硫原子或 NR3a（其中 R3a 是可被取代的烃基或氢原子），以及 Ya 是可被取代的 C1-6 亚烷基或键，或其盐或原药。
• FUSED RING LACTAM DERIVATIVES
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：EP3828182A1

  公开（公告）日：2021-06-02

  The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.

  本发明涉及一种治疗神经精神疾病的药物，由式（1）化合物组成： 或其药学上可接受的盐作为活性成分。
• Condensed lactam derivative
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US10745401B2

  公开（公告）日：2020-08-18

  The present invention relates to a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1): or a pharmaceutically acceptable salt thereof, as an active ingredient.

  本发明涉及一种治疗神经精神疾病的药物，由式（1）化合物组成： 或其药学上可接受的盐作为活性成分。